Allison and Amber Westemeier get excited every time they take a trip to the Waisman Center from Oshkosh, WI.
Down Syndome
Weight loss may be early predictor of Alzheimer’s disease in Down syndrome
Unintentional weight loss in people with Down syndrome may predict the onset of Alzheimer’s disease long before typical cognitive symptoms like memory loss and dementia are apparent.
Thoughts of gratitude: The Dewey family is a catalyst of support for the Waisman Center
Individuals with Down syndrome are at higher risk of developing Alzheimer’s disease, and it typically presents it at an earlier age than the general population. It is estimated that 90% of people with Down syndrome will have developed Alzheimer’s by age 65.
Sigan Hartley, PhD – Slide of the Week
People with Down Syndrome (DS) are at high risk for Alzheimer’s disease (AD) because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD.
Xinyu Zhao, PhD – Slide of the Week
Neurodevelopmental impairment contributes to the hallmark cognitive disability in individuals with Down syndrome (DS, trisomy 21, T21).
New study reveals changes in key pathway in Down syndrome
A new paper published by Anita Bhattacharyya, PhD reveals that the differences in brain structure in individuals with Down syndrome (DS or Trisomy 21) may be due to disrupted signaling pathways that alter brain development to result in the incorrect number or placement of cells in the brain.
Jose Martinez connects science and policy as a BTP trainee
While working as a health care administrator in Santa Cruz, California during the 2015 Zika virus outbreak, Jose Martinez realized his background in chemistry and pharmacology could be harnessed to set policies that are grounded in science.
Bradley T Christian, PhD – Slide of the Week
Adults with Down syndrome (DS) are predisposed to Alzheimer’s disease (AD) and a characterization of glucose metabolism change throughout AD progression has yet to be performed in this population. Using FDG PET, regional glucose metabolism was evaluated across groups of cognitively stable DS (CS-DS), DS with mild cognitive impairment or Alzheimer’s disease (MCI-DS/AD), and healthy non-DS sibling controls.